Want to see HK:2179 full AI Analyst Report?
2179 Stock Chart & Stats
HK$4.18
-HK$0.53(-6.02%)
At close: 4:00 PM EST
HK$4.18
-HK$0.53(-6.02%)
Day’s Range― - ―
52-Week RangeHK$3.40 - HK$7.78
Previous CloseN/A
Volume13.00K
Average Volume (3M)433.00
Market Cap
HK$3.04B
Enterprise ValueHK$3.46K
Total Cash (Recent Filing)HK$187.51M
Total Debt (Recent Filing)HK$672.99M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding458,092,160
10 Day Avg. Volume150
30 Day Avg. Volume433
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.93
Revenue Forecast (FY)HK$11.00M
Bulls Say, Bears Say
Bulls Say
Improved LeverageA meaningful year-over-year reduction in debt-to-equity materially lowers financial risk and interest burden, improving flexibility. Durable impact: with lower leverage the company can better withstand biotech R&D cycles, access capital on firmer terms, and extend runway for clinical and commercialization milestones.
Integrated Vaccine PlatformOwning R&D, manufacturing and commercialization capabilities creates a durable competitive advantage in biologics: it reduces reliance on external CDMOs, speeds regulatory and supply responses, and supports scaling successful candidates to market, improving long-term control over margins and timing.
Improving Free Cash Flow TrendAn improving free-cash-flow trend, even from negative levels, signals early operational or efficiency gains. If sustained, this reduces cash burn and external funding needs, strengthening solvency and enabling reinvestment in core programs — a durable positive for execution risk.
Bears Say
Persistent Cash BurnChronic negative operating and free cash flow forces dependence on external financing, raising dilution and execution risk. Over the medium term this constrains R&D and commercialization pacing, increases refinancing exposure, and can limit the ability to capitalize on growth opportunities.
Volatile, Shrinking Revenue And Negative Gross ProfitA sharp revenue decline and negative gross profit point to weak commercialization, pricing, or cost control. This undermines margin sustainability and revenue visibility; without consistent product-market traction, scale benefits and durable profitability remain uncertain over the next several quarters.
Shrinking Asset Base And Negative ReturnsA declining asset base alongside strongly negative ROE indicates capital erosion from recurring losses and asset drawdown. Structurally, this weakens balance sheet resilience, reduces capacity to fund pipelines internally, and raises the probability of equity dilution or asset sales to sustain operations.
Jiangsu Recbio Technology Co., Ltd. Class H News
2179 FAQ
What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$3.40 and its highest was HK$7.78 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$3.04B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 192 days.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Aug 19, 2026. The company reported -HK$0.398 earnings per share for the quarter.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Recbio Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 458,092,160 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.398 in its last earnings report. Following the earnings report the stock price went down -2.057%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Recbio Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Technical Analysis
Genor Biopharma Holdings Limited
―
TOT BIOPHARM International Co. Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Clover Biopharmaceuticals Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―